

and recrystallized from absolute ethanol.

1,4-Bis[(6-methoxy-8-quinoly)aminoalkyl]piperazines (Table I, 2-4). An intimate mixture of the appropriate piperazine 12-14 (1 equiv) and 6-methoxy-8-aminoquinoline (6 equiv) was heated under nitrogen at 120-125° for 19 hr. The melt was cooled at room temperature, rendered basic with 1 *N* NaOH, and extracted with CHCl₃. After drying (MgSO₄), the CHCl₃ was removed *in vacuo* and the oily residue dissolved in ethanol and treated with excess alcoholic oxalic acid. The insoluble precipitate (oxalate salt of the desired product, *e.g.*, 2) was collected. Unreacted 6-methoxy-8-aminoquinoline remained in solution as the oxalate salt. The alcoholic insoluble product was stirred with 10% NaOH solution for 0.5 hr and filtered. The solid residue was dissolved in benzene, treated with charcoal, and concentrated *in vacuo*, and the free amine precipitated with *n*-hexane. The analytical sample was prepared by several reprecipitations from benzene by hexane.

In the preparation of 3 and 4, it was not necessary to prepare oxalate salts to separate product from unreacted 6-methoxy-8-aminoquinoline. The product solidified in a fairly pure state when the oily residue was treated with ether.

Acknowledgments. We acknowledge the U. S. Army Medical and Development Command under Contract DADA 17-71-C-1068 for support of this work. This is Contribution No. 1178 from the Army Research Program on Malaria. The authors wish to thank Drs. R. E. Strube and T. R. Sweeney of WRAIR for interest and encouragement during the course of this work.

References

- (1) (a) E. F. Elslager in "Progress in Drug Research," Vol. 13, E. Juckel, Ed., Birkhauser-Verlag, Basel, Switzerland, 1969, p. 170; (b) R. M. Pinder in "Progress in Medicinal Chemistry," Vol. 8, G. P. Ellis and G. B. West, Ed., Butterworths, London, 1971, p. 231; (c) P. E. Thompson and L. M. Werbel, "Antimalarial Agents," Academic Press, New York, N. Y., 1972.
- (2) T. R. Castles, E. Loth, C. R. Crawford, and C. C. Lee, *J. Pharmacol. Exp. Ther.*, 172, 44 (1970).
- (3) S. P. James, *Trans. Roy. Soc. Trop. Med. Hyg.*, 27, 477 (1931); P. B. Russell in "Medicinal Chemistry," 2nd ed., A. Burger, Ed., Interscience, New York, N. Y., 1960, p. 829.
- (4) S. M. Talati, M. R. Latham, E. G. Moore, G. W. Hargreaves, and C. D. Blanton, Jr., *J. Pharm. Sci.*, 59, 491 (1970).
- (5) (a) L. P. Walls, British Patent 834,300 (1960); *Chem. Abstr.*, 54, 24822 (1960); (b) G. R. Coatney, W. C. Cooper, N. B. Eddy, and J. Greenberg, "Survey of Antimalarial Agents," Public Health Monograph No. 9, U. S. Government Printing Office, Washington, D. C., 1953.
- (6) S. Groszkowski, J. Sienkiewicz, L. Najman, R. Oteleanu, and M. Retezeanu, *J. Med. Chem.*, 11, 621 (1968).
- (7) J. L. Neumeyer and K. K. Weinhardt, *ibid.*, 13, 999 (1970).
- (8) T. S. Osdene, P. B. Russell, and L. Rane, *ibid.*, 10, 431 (1967).
- (9) (a) L. Rane and D. S. Rane, *Proc. Helminthol. Soc. Washington*, 39, 283 (1972); (b) M. E. King, A. M. Shefner, and M. D. Schneider, *ibid.*, 39, 288 (1972).
- (10) J. Meisenheimer, L. Angermann, O. Finn, and E. Vieweg, *Chem. Ber.*, 57, 1753 (1924).
- (11) (a) J. H. Gardner and J. H. Schneider, *J. Amer. Chem. Soc.*, 55, 3823 (1933); (b) S. M. McElvain and L. W. Banister, *ibid.*, 76, 1126 (1954).
- (12) H. D. Dell, *Naturwissenschaften*, 53, 405 (1966).

Preliminary Pharmacology of Some Benzocycloheptane Derivatives Related to Amphetamine

R. M. Parkhurst,* Priscilla A. Sturm, Howard Johnson, and W. A. Skinner

Life Sciences Division, Stanford Research Institute, Menlo Park, California 94025. Received February 13, 1973

Recent interest in drug abuse and the quest for compounds that may act as blocking agents for drugs, such as the amphetamines, has brought forth a number of com-

pounds which show some activity in this regard. Various simple trimethoxybenzamides exhibit mild sedative properties¹ and are capable of antagonizing the action of amphetamine.² In contrast to the psychomimetic activity of 3,4-dimethoxyamphetamine, β -(3,4-dimethoxyphenyl)-2-propanol, the oxygen analog, is a CNS depressant.³ The *N,N*-diallyl derivative of amphetamine has been reported to have antagonistic activity toward amphetamine.⁴ Other more complicated *N*-substituted amphetamines and amphetamine derivatives show antagonistic activity.^{5,6}

During the course of work not related to drug abuse, a series of compounds was generated and given a preliminary screening for pharmacological activity in mice. All of these compounds are benzocycloheptane derivatives with methoxy and/or hydroxy substitution on the benzene ring and are easily obtained in good yield from purpurogallin. Their relationship to amphetamine prompts us to publish the preliminary pharmacology.

Results and Discussion

Amphetamine exhibited a spectrum of pharmacological effects (Table I) which included those most clearly referable to CNS stimulation (b, d, and h). On the basis of these effects, compounds 19 and 21 most closely approximated amphetamine while compounds 5 (h) and 6 (b, h) also appeared to be predominantly stimulant. None of the other compounds exhibited any of these properties and all except 18 showed at least one opposing effect referable to CNS depression. Compound 9 appeared to be the most clearly depressant (a, c, l).

It is of interest that substitution of OH for OCH₃ at R₁ in most compounds had little effect on activity or enhanced depressant effects (16 *vs.* 9) but reversed activity in one case (13 *vs.* 6). The slight stimulant activity of 5 was enhanced in R₁-methylated derivatives with appropriate substitution adjacent to the keto function (19) even when the latter was enolized in lactone formation (21). Interestingly, however, stimulant activity was absent in the corresponding lactam 22 and in the carboxyl analog 20 of the nitrile 19. It is possible that limitations on the stimulant actions of 19 and 21 could result *in vivo* from nitrile and lactone hydrolysis, respectively, which would yield inactive 20 in each case.

Experimental Section

Purpurogallin (1). Purpurogallin was made from pyrogallol by the method of Evans and Dehn⁷ in 92% crude yield and used without further purification.

Purpurogallin Trimethyl Ether (2). Purpurogallin trimethyl ether was made⁸ from purpurogallin (1) in 30% yield after recrystallization from methanol as long orange needles, mp = 179-180° (lit. mp 174°).

4-Hydroxy-5-oxo-2,3,6-trimethoxybenzocycloheptane (3). Purpurogallin trimethyl ether (2) was converted to 3 by the method described by Walker⁹ in 58% yield of colorless plates melting at 78-80° (lit. mp 86-88°).

4,5-Dihydroxy-2,3,6-trimethoxybenzocycloheptane (4). This material was made from 3 by the method described by Barltrop and Nicholson¹⁰ and recrystallized from ethanol in 90% yield to give a product melting at 145-147° (lit. mp 148°).

2,3-Dimethoxy-4-hydroxy-6-oxobenzocycloheptane (5). This material was made from 4 by methods described in the literature⁸ in 72% yield and melted at 140-145° (lit. mp 140-141°).

2,3-Dimethoxy-4-hydroxy-6-semicarbazobenzocycloheptane (6). To 809.9 mg (3.4 mmol) of the hydroxy ketone 5 dissolved in hot ethanol was added about 2 ml of water, 1.0 g (9 mmol) of semicarbazide hydrochloride, and 1.5 g (11 mmol) of sodium acetate. The mixture was heated on a steam bath and almost immediately white crystals formed. After heating an additional 15 min, cooling and filtering gave 882.1 mg (88%) of white crystals melting at 220-223°.

2,3-Dimethoxy-4-hydroxy-6-thiosemicarbazobenzocycloheptane (7). The hydroxy ketone 5 (1.0 g, 4.2 mmol) was dissolved in hot ethanol and water added until just cloudy.

Table I. Pharmacological Results

Compd	R ₁	R ₂	LD ₅₀ , mg/kg	MED ₅₀ , mg/kg	Effects ^a	Formula	Analyses
5	-OH	=O	>100	31.6	g, efjih	C ₁₃ H ₁₆ O ₄	
6	-OH	=NNHCONH ₂	>100	0.237	g, bhi	C ₁₄ H ₁₉ N ₃ O ₄	C, H, N
7	-OH	=NNHCSNH ₂	>100	5.62	c	C ₁₄ H ₁₉ N ₃ O ₃ S	C, H, N, S
8	-OH	=NOH	>100	<1.0	g, cfej	C ₁₃ H ₁₇ NO ₄	C, H, N
9	-OH	-NH ₂	70.8	<1.0	g, acлкеf	C ₁₃ H ₁₇ NO ₃	C, H, N
10	-OH	-NHCO ₂ CH ₃	44.7	1.78	f, ac	C ₁₅ H ₂₁ NO ₅	C, H, N
11	-OH	-NHCH ₃	70.8	31.6	f, a	C ₁₄ H ₂₁ NO ₃	C, H, N
13	-OCH ₃	=NNHCONH ₂	>100	31.6	f, aj	C ₁₅ H ₂₁ N ₃ O ₄	C, H, N
14	-OCH ₃	=NNHCSNH ₂	>100	5.62	c, af	C ₁₅ H ₂₁ N ₃ O ₃ S	C, H, N, S
15	-OCH ₃	=NOH	31.6	1.78	a, g	C ₁₄ H ₁₉ NO ₄	
16	-OCH ₃	-NH ₂	79.4	0.464	a, f	C ₁₄ H ₂₂ ClNO ₃	C, H
17	-OCH ₃	-NHCO ₂ CH ₃	79.4	10.0	e, ac	C ₁₆ H ₂₃ NO ₅	C, H, N
18	-OCH ₃	-NHCH ₃	63.1	5.62	f, efg	C ₃₂ H ₄₅ N ₂ O ₁₀	C, H, N
		R ₃					
19		-CH ₂ CH ₂ CN	>100	0.056	h, bd	C ₁₇ H ₂₁ NO ₄	
20		-CH ₂ CH ₂ CO ₂ H	>100	31.6	e, acf	C ₁₇ H ₂₂ O ₆	
		Y					
21		>O	>100	3.16	e, bdmhf	C ₁₇ H ₂₀ O ₅	
22		>NCH ₃	>100	5.62	c, afg	C ₁₅ H ₂₃ NO ₄	C, H
		<i>l</i> -α-Methylphenethylamine ^b	>100	0.29	h, bdef		

^aa = CNS depression (subjective; startle response, righting reflex, etc.); b = CNS stimulation (subjective; startle response, righting reflex, etc.); c = decreased activity (compartmental observation); d = increased activity (compartmental observation); e = ataxia; f = motor deficit (grasp reflex, traction, complex coordination on horizontal rigid wire, rotating rod); g = decreased muscle tone (trunk and limb); h = increased sensitivity in touch and sound (reactivity); i = piloerection; j = low posture; k = color change to red; l = decreased sensitivity to touch and sound (reactivity); m = increased muscle tone (trunk and limbs). ^bAldrich Chemical Co.

Thiosemicarbazide hydrochloride (1.0 g, 7.9 mmol) was added along with 1 drop of acetic acid and heating on the steam bath continued for 20 min. The mixture was placed in an ice bath and 1.78 g of crude crystals removed by filtration. Several recrystallizations from methanol-water gave product melting at 192–194°.

2,3-Dimethoxy-4-hydroxy-6-oximidobenzocycloheptane (8). The hydroxy ketone 5 (2.48 g, 10.5 mmol), 25 ml of 10% NaOH (62.5 mmol), and 6.3 g (90 mmol) of hydroxylamine hydrochloride were mixed with enough warm ethanol to make a clear solution. The mixture was allowed to stir at steam bath temperatures for 1 hr. Cooling the solution with ice and scratching with a glass rod caused it to deposit colorless crystals, 1.93 g (73%), mp 169.5–176°.

6-Amino-2,3-dimethoxy-4-hydroxybenzocycloheptane (9). The oxime 8 (457 mg, 1.8 mmol) in 25 ml of methanol with 0.5 g of Raney nickel was hydrogenated at room temperature and atmospheric pressure. After the uptake of the theoretical amount of hydrogen (overnight) the solvent was removed *in vacuo* and the product crystallized from ethanol-ether to give 259 mg (60% yield) of white crystals (mp 153–154°).

6-N-Carbomethoxyamino-2,3-dimethoxy-4-hydroxybenzocycloheptane (10). To 1.27 g (5.4 mmol) of amine 9 was added 10 ml of water and 4.3 ml (10 mmol) of a sodium hydroxide solution (10%). To the resulting clear yellow solution was added dropwise 15 ml of chloroform containing 0.4 ml (5.4 mmol) of methyl chloroformate and the mixture allowed to stir overnight at room temperature. The reaction mixture was cooled to 0° in an ice bath and slowly acidified (pH 2) with dilute hydrochloric acid. After stirring for 1 hr, the layers were separated and the aqueous phase was extracted with chloroform. The combined chloroform layers were washed with water, dried with sodium sulfate, and evaporated *in vacuo*. The yellowish solid was recrystallized from benzene-ether-light petroleum yielding 0.545 g (35%) of cream-colored crystals (mp 133–135°).

2,3-Dimethoxy-4-hydroxy-6-methylaminobenzocycloheptane (11). To 1.36 g (36 mmol) of LiAlH₄ in 50 ml of dry tetrahydrofuran cooled to 0° was added dropwise 1.0 g (3.4 mmol) of the carbamate 10 dissolved in 15 ml of dry tetrahydrofuran. The mixture was stirred for 0.5 hr and then overnight at room temperature.

The mixture was refluxed for 3 hr. The reaction was terminated with 1 ml of water in 15 ml of tetrahydrofuran and made filterable by adding 5 ml of 12% sodium hydroxide, followed by 1 ml of water, stirred 1 hr, and filtered. After washing and drying, the extract was evaporated to yield a viscous yellow oil which crystallized to give 134.9 mg (16%) of white crystals (mp 171–174°).

6-Oxo-2,3,4-trimethoxybenzocycloheptane (12). This material was made from the hydroxy ketone 5 by the method of Rapoport and Campion¹¹ in 88% yield to give a product melting at 53.5–55° (lit. mp 46–46.5°).

6-Semicarbazono-2,3,4-trimethoxybenzocycloheptane (13). The semicarbazone was made from the ketone 12 as previously described¹¹ in 92% yield and recrystallized several times from methanol-water to give a product melting at 192–200° (lit. mp 184–185°).

6-Thiosemicarbazono-2,3,4-trimethoxybenzocycloheptane (14). The thiosemicarbazone was made as usual from the ketone 12 and crystallized from methanol-water as colorless crystals melting at 212–214° in 54% yield.

6-Oxido-2,3,4-trimethoxybenzocycloheptane (15). This material was made as previously described¹¹ from the ketone 12 in 90% yield to give a product melting at 130–137° (lit. mp 130.5–131°).

6-Amino-2,3,4-trimethoxybenzocycloheptane (16). The oxime 15 (2.0 g, 7.5 mmol) dissolved in 100 ml of ethanol and 2.0 g of Raney nickel was hydrogenated at room temperature and atmospheric pressure overnight. After the theoretical amount of hydrogen was taken up, the catalyst was filtered off and the solvent evaporated *in vacuo*. A colorless oil remained. The oil was taken up in ether and isolated as the hydrochloride, 1.2 g (58%), melting at 226–230°.

6-(N-Carbomethoxy)amino-2,3,4-trimethoxybenzocycloheptane (17). To 2 g (7 mmol) of amine hydrochloride 16 in 30 ml of chloroform-water (1:1) mixture was added 0.53 ml (7 mmol) of methyl chloroformate. To this mixture was added 8.4 ml (21 mmol) of 10% NaOH solution and the mixture stirred for 2 hr at room temperature. Dilute hydrochloric acid was added to the ice-cold reaction mixture to pH 2. The layers were separated, the aqueous phase was extracted with chloroform, and the chloroform

was washed with water, dried, and evaporated *in vacuo*. The product, 1.89 g of pale yellow oil, was crystallized from benzene-light petroleum mixtures to give 0.994 g of colorless crystals melting at 114–116.5°.

6-(*N*-Methylamino)-2,3,4-trimethoxybenzocycloheptane (18). The carbamate 17 (820 mg 2.7 mmol) dissolved in 15 ml of dry tetrahydrofuran was slowly added dropwise to 1.3 g (34 mmol) of LiAlH₄ suspended in 15 ml of dry tetrahydrofuran cooled to 0°. The mixture was stirred 0.5 hr at 0° after which time it was refluxed for 2 hr. The reaction was terminated by adding 1.3 ml of water in 10 ml of tetrahydrofuran and made filterable with 5 ml of 12% NaOH. After filtering, drying, and evaporating 643 mg (91%) of yellow oil was obtained. The compound was isolated as the oxalate, mp 195–205°.

5- β -Cyano-6-oxo-2,3,4-trimethoxybenzocycloheptane (19). This compound was made as already described¹² from the ketone 12 in 98% crude yield. Recrystallization from ethanol gave a product melting at 107–110° (lit. mp 110.5–111.2°).

3-(6-Oxo-2,3,4-trimethoxybenzocycloheptan-5-yl)propionic Acid (20). Compound 20 was made from the hydrolysis of the cyano ketone 19 by methods already described¹² in nearly quantitative yield. The ir spectrum was as expected, mp 87–89° (lit. mp 88–90°).¹²

β -[5-(6-Hydroxy-2,3,4-trimethoxybenzocyclohepten-5-yl)]-propionic Acid δ -Lactone (21). This product was made from the keto acid 20 by previously described methods¹² in 59% yield of material melting at 105–107° (lit. mp 104–105°).

β -[5-(6-Hydroxy-2,3,4-trimethoxybenzocyclohepten-5-yl)]-propionic Acid δ -*N*-Methylactam (22). The crude keto acid 20 (528 mg, 1.6 mmol) was added to 25 ml of ethanol which had been saturated with methylamine. The mixture was heated in a stainless steel bomb at 140° for 8 hr. The product remaining after the evaporation of the ethanol was purified by chromatography on a silica gel plate using chloroform as a solvent (*R_f* = 0.05–0.25). The product was removed from the plate and crystallized from light petroleum to give 230 mg (44%) of colorless microcrystals which melted at 104–106°. The ir spectrum was as expected.

Biological Evaluation. Male albino mice of the Swiss-Webster strain weighing 20–25 g were used. All injections were *via* the intravenous route (tail) in volumes not exceeding 0.01 ml/g of body weight. Testing protocol consisted of suspending or dissolving all compounds in water or 0.5% methylcellulose. Approximate 0.5 log-spaced doses were employed to characterize a "no effect" to 100% lethal response. Four animals were used at each dose level. Each animal was evaluated for significant activity at 5, 10, 15, 30, and 60 min postinjection and thereafter at 2, 4, and 24 hr. The statistical method, employed for the calculation of LD₅₀ and MED₅₀, is that described by Weil.¹⁴ The MED₅₀ shown in Table I is based on the first pharmacological effect shown in the "effects" column; other effects (those shown after the comma) may or may not be observed at the MED₅₀ dose. The MED₅₀ is based on the pharmacological effect shown at the lowest dose which gave any clear effect.

Acknowledgment. The authors are indebted to Miss Zelma Dunn, Dr. Sam Ferguson, and Mr. David Kay for biological testing, to Miss E. M. McCarthy for elemental analysis, and Stanford Research Institute general development funds for support of this work.

References

- W. A. Skinner, J. Kennedy, J. I. DeGraw, and H. Johnson, *J. Med. Chem.*, **12**, 715 (1969).
- E. Palosi, C. Meszaros, and L. Szporny, *Arzneim.-Forsch.*, **19**, 1882 (1969).
- C. F. Barfknecht, J. M. Miles, and J. L. Leseney, *J. Pharm. Sci.*, **59**, 1842 (1970).
- E. Fox, E. Lynch, M. Theisen, and M. M. Christine, *Prac. Ioua Acad. Sci.*, **67**, 206 (1960).
- S. Jespersen and A. Bonaccorsi, *Eur. J. Pharmacol.*, **8**, 364 (1969).
- R. Ferrini, G. Miragoli, and G. Croce, *Arzneim.-Forsch.*, **20**, 1075 (1970).
- T. W. Evans and W. M. Debn, *J. Amer. Chem. Soc.*, **52**, 3647 (1930).
- J. Schreiber, W. Leimgruber, M. Pesaro, P. Schudel, T. Threlfall, and A. Eschenmoser, *Helv. Chim. Acta*, **44**, 540 (1961).
- G. N. Walker, *J. Amer. Chem. Soc.*, **77**, 6699 (1955).
- J. A. Barltrop and J. S. Nicholson, *J. Chem. Soc.*, 116 (1948).
- H. Rapoport and J. E. Campion, *J. Amer. Chem. Soc.*, **73**, 2239 (1951).
- E. F. van Tamelen, T. A. Spencer, Jr., D. S. Allen, Jr., and R. L. Orvis, *Tetrahedron*, **14**, 8 (1961).
- J. Martel, E. Toromanoff, and C. Huynh, *J. Org. Chem.*, **30**, 1752 (1965).
- C. S. Weil, *Biomemories*, **8**, 249 (1952).

Puromycin Analogs. I Synthesis and Biological Activity of 5'-Deoxypuromycin and Its Aminonucleoside, 6-Dimethylamino-9-(3'-amino-3',5'-dideoxy- β -D-ribofuranosyl)purine†

Ronald G. Almquist and Robert Vince*

Department of Medicinal Chemistry, College of Pharmacy,
University of Minnesota, Minneapolis, Minnesota 55455.
Received July 13, 1973

The antibiotic puromycin derives its antimicrobial and antitumor activity from its ability to cause a premature release of growing polypeptide chains from ribosomes.² The aminonucleoside derived from puromycin is devoid of antibacterial activity but is three to four times as cytotoxic as the parent antibiotic against mammalian cells.³ Consequently, an additional cytotoxic effect on the host may result from the release of aminonucleoside if hydrolytic or enzymatic removal of the amino acid moiety from administered puromycin occurs⁴ (Figure 1). Recent studies demonstrate that the aminonucleoside is monodemethylated⁵ and subsequently converted to the 5'-nucleotide.⁶ It is not unreasonable to assume, therefore, that nucleotide formation is a prerequisite to cytotoxic activity. This same metabolic scheme may also account for the severe nephrotoxic manifestations, including renal lesions, resulting from administered puromycin aminonucleoside.

In an attempt to improve the selective toxicity of the antibiotic, an assessment of the requirement for the 5'-OH in both the antimicrobial activity of puromycin and in the cytotoxic activity of the aminonucleoside is desirable. Previous studies with carbocyclic analogs have been useful in defining the ribosomal binding requirements of the antibiotic.⁷ However, the absence of a sugar moiety in these analogs precludes the assessment of the 5'-OH group's contribution to the cytotoxic effect. Thus, we have developed




Figure 1.

†This investigation was supported by Research Career Development Award CA25258 and Grant CA13592 from the National Cancer Institute, and Training Grant 5 T01 GM02064 from the National Institutes of Health, U. S. Public Health Service.